Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing
Posted:
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.
Read the full article in the latest MedCity News blog post here.
A new AI framework can detect neurological disorders by analyzing speech with over 90% accuracy. The model, called CTCAIT, captures subtle patterns in voice that may indicate early symptoms of diseases like Parkinson’s, Huntington’s, and Wilson disease.
Read more here.